Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma

(2016) Siyuan Zheng et al.   CANCER CELL

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses

(2016) Leandro M. Colli et al.   CANCER RESEARCH

Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab

(2016) Swati Khanna et al.   Journal of Thoracic Oncology

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

(2015) Martin Fassnacht et al.   LANCET ONCOLOGY

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

(2015) André P Fay et al.   Journal for ImmunoTherapy of Cancer

The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer

(2014) Ciara O'Sullivan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

(2013) A Naing et al.   BRITISH JOURNAL OF CANCER

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial

(2012) Matthias Kroiss et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

(2012) Martin Fassnacht et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

(2011) Alfredo Berruti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Current and Emerging Therapies for Advanced Adrenocortical Carcinoma

(2011) L. J. Tacon et al.   ONCOLOGIST

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

(2010) Paola Sperone et al.   ENDOCRINE-RELATED CANCER

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma

(2009) Sebastian Wortmann et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine

(2008) Marcus Quinkler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM